Skip to main content

Table 13 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the Barthel Index, for the subgroup in Netherlands

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
Barthel Index
 Improved 0.79 0.88 0.09 (0.00 to 0.18) 0.58 11 55
 No change 0.87 0.90 0.02 (− 0.01 to 0.07) 0.22 37 41
 Worsened 0.69 0.63 − 0.03 (− 0.13 to 0.07) − 0.10 15 40
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
Barthel Index
 Improved 0.73 0.85 0.12 (0.02 to 0.22) 0.78 11 64
 No change 0.84 0.87 0.03 (− 0.01 to 0.08) 0.21 37 43
 Worsened 0.68 0.62 − 0.06 (− 0.15 to 0.03) − 0.21 15 27
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large